News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Chimeric Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York
News
ASX Small Caps Lunch Wrap: Whose eight-year world record dream has gone up in smoke this week?
Health & Biotech
ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia
News
Top 10 at 11: Battery metals, exploration and drug trials make the news today
Experts
Money Talks: Keep an eye on these tasty precious metal and biotech plays in 2024
News
Closing Bell: Material losses and profit taking at home ahead of Thanksgiving in New York
News
Small Caps Lunch Wrap: ASX down, Commodities depressed, Gregor has Covid… The only thing doing good is inflation
Health & Biotech
ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy
News
Top 10 at 11: Boron, lithium and a biotech breakthrough are driving the market this morning
Health & Biotech
ASX Health Stocks: Island Pharma granted Aussie patent for flavivirus infection drug, ISLA-101
Health & Biotech
ASX Biotech October Winners: Dimerix, Noxopharm and Chimeric dominate as investors hunt next big thing in pharma
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Cap Lunch Wrap: Benchmark higher as Chimeric stock finds huge support ‘cos even investors hate cancer
Health & Biotech
ASX Health Stocks: Chimeric surges 70pc after FDA approval, takes its CAR T cell drug to the clinic
News
Top 10 at 11ish: Chimeric Therapeutics soars 58pc on US FDA clearance
News
Top 10 at 11: Nimy soars after ‘clear game-changer’ nickel-copper sulphides find
News